EP Patent

EP1042325B1 — Nitrogen-containing heterocyclic compounds, their production and use

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2005-09-21 · 21y expired

What this patent protects

A compound of the formula: wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R<SUP>1</SUP>, R<SUP>2 </SUP>and R<SUP>3 </SUP>each is (i) H or (ii) a group bound via C, N, O or S; R<SUP>4 </SUP>is a…

USPTO Abstract

A compound of the formula: wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R<SUP>1</SUP>, R<SUP>2 </SUP>and R<SUP>3 </SUP>each is (i) H or (ii) a group bound via C, N, O or S; R<SUP>4 </SUP>is a group bound via C; R<SUP>5 </SUP>is H or a group bound via C or O; R<SUP>6 </SUP>is H or a group bound via C; R<SUP>7 </SUP>is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.

Drugs covered by this patent

Patent Metadata

Patent number
EP1042325B1
Jurisdiction
EP
Classification
—
Expires
2005-09-21
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.